Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Canadian Fintech RevoluGROUP targeted in the heated M&A takedown

2022 has seen its fair share of mergers and acquisitions in the Fintech world. But the year isn’t over yet; there could be yet another, and this time it’s a Canadian Fintech. A little-known...

Software For Safe Medical Cannabis Access

Alternate Health’s integrated health services features clinical laboratories and CanaPass - online patient management software for safe access to medical cannabis. Currently generating revenue, Alternate Health plans to reinvest profit...

Targeted exploration unearthing new lithium resources in Ontario

Imagine Lithium (TSXV:ILI) is a Canadian junior exploration company focused on advancing its flagship Jackpot Lithium Project in Ontario.The property contains known lithium bearing granitic...

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturna...

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. In a June 14 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Kura Oncology Inc. (KURA:NASDAQ) met the endpoint in its Phase 2 clinical trial of...

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...

Positive Cash Flow Extractor Manufacturer Turns its Mind to Psychedelics

“It’s all about visibility.” That’s how Calgary, AB-based MedXtractor Corp. (MXT) ( CSE.MXT , Forum ) is changing both the future of cannabis extraction and the burgeoning mental health science of psychedelics. ...

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. Clinical-stage biotechnology...

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. This morni...
1 2 3 4 5 6 7 8 9 10 ...